endometrial adenocarcinoma (Cancer)
Information
- Disease name
- endometrial adenocarcinoma
- Disease ID
- DOID:2870
- Description
- "An endometrial carcinoma that derives_from epithelial cells of glandular origin." [url:http\://en.wikipedia.org/wiki/Adenocarcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00977574 | Active, not recruiting | Phase 2 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | September 14, 2009 | March 6, 2025 |
| NCT03586661 | Active, not recruiting | Phase 1 | Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | April 29, 2019 | December 31, 2026 |
| NCT02208375 | Active, not recruiting | Phase 1/Phase 2 | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | November 11, 2014 | December 30, 2025 |
| NCT04106414 | Active, not recruiting | Phase 2 | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | September 24, 2019 | September 2024 |
| NCT03660826 | Active, not recruiting | Phase 2 | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | September 27, 2018 | December 31, 2024 |
| NCT03460483 | Active, not recruiting | N/A | Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care | March 30, 2018 | June 30, 2023 |
| NCT00072176 | Completed | Phase 2 | Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer | May 2004 | August 2009 |
| NCT00095979 | Completed | Phase 2 | Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer | May 2005 | July 2009 |
| NCT00478426 | Completed | Phase 2 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | April 30, 2007 | February 12, 2019 |
| NCT00814086 | Completed | Phase 1 | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | February 2009 | |
| NCT00002706 | Completed | Phase 3 | Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus | April 1996 | |
| NCT00888173 | Completed | Phase 2 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | July 6, 2009 | July 16, 2016 |
| NCT01005329 | Completed | Phase 2 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | November 6, 2009 | September 22, 2013 |
| NCT01011933 | Completed | Phase 2 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 2009 | January 2016 |
| NCT01132820 | Completed | Phase 2 | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer | June 2010 | January 2016 |
| NCT01208467 | Completed | Prognostic Biomarkers in Patients With Endometrial Cancer | September 2010 | ||
| NCT01210222 | Completed | Phase 2 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | June 6, 2011 | July 16, 2016 |
| NCT01225887 | Completed | Phase 2 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | October 2011 | January 2016 |
| NCT01307631 | Completed | Phase 2 | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer | March 2011 | September 18, 2015 |
| NCT01440998 | Completed | Phase 1 | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | September 20, 2011 | December 31, 2015 |
| NCT01642082 | Completed | Phase 2 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 2012 | January 2016 |
| NCT01935973 | Completed | Phase 1 | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 30, 2013 | September 8, 2015 |
| NCT01968317 | Completed | Phase 2 | Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma | October 2013 | October 2017 |
| NCT02549209 | Completed | Phase 2 | Pembro/Carbo/Taxol in Endometrial Cancer | August 22, 2017 | February 10, 2022 |
| NCT03164590 | Completed | Phase 4 | Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines | June 1, 2017 | September 1, 2018 |
| NCT00820898 | Completed | Phase 2 | Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer | February 2009 | |
| NCT00005830 | Completed | Phase 1 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | July 2000 | |
| NCT00006011 | Completed | Phase 3 | Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | July 2000 | |
| NCT00006089 | Completed | Phase 2 | Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | September 18, 2000 | January 31, 2010 |
| NCT00025467 | Completed | Phase 2 | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 2001 | |
| NCT00064025 | Completed | Phase 2 | Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | April 2004 | |
| NCT03716414 | Completed | Evaluation of the Efficacy for Sentinel Lymph Node Policy in High-risk Endometrial Carcinoma | November 1, 2018 | February 16, 2020 | |
| NCT04873206 | Completed | Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies | January 1, 2020 | December 31, 2020 | |
| NCT04972682 | Completed | N/A | [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer | July 1, 2021 | April 15, 2024 |
| NCT06066216 | Not yet recruiting | Phase 2 | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer | February 1, 2024 | October 31, 2026 |
| NCT05824481 | Not yet recruiting | Phase 2 | Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer | June 1, 2023 | June 30, 2026 |
| NCT06399757 | Not yet recruiting | Phase 1/Phase 2 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | May 2024 | May 2027 |
| NCT05112601 | Recruiting | Phase 2 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | June 2, 2022 | April 30, 2026 |
| NCT05001282 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | September 13, 2021 | June 15, 2025 |
| NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
| NCT05548296 | Recruiting | Phase 1/Phase 2 | A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma | August 29, 2022 | December 31, 2027 |
| NCT05655260 | Recruiting | N/A | PErsonalized TReatment for Endometrial Carcinoma | February 8, 2022 | December 31, 2028 |
| NCT01041027 | Terminated | Phase 2 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer | January 16, 2009 | October 1, 2019 |
| NCT02065687 | Unknown status | Phase 2/Phase 3 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | March 17, 2014 | September 13, 2023 |
| NCT03221400 | Unknown status | Phase 1/Phase 2 | PEN-866 in Patients With Advanced Solid Malignancies | August 29, 2017 | June 2023 |
| NCT01943058 | Withdrawn | Phase 2 | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer | March 2014 | October 2017 |
| NCT03836157 | Withdrawn | Phase 2 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | May 31, 2019 | May 2022 |
- Disase is a (Disease Ontology)
- DOID:2871
- Cross Reference ID (Disease Ontology)
- NCI:C6287
- Cross Reference ID (Disease Ontology)
- NCI:C6290
- Cross Reference ID (Disease Ontology)
- NCI:C7359
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:123845008
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:1260086007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0279763
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1153706
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1336905
- Exact Synonym (Disease Ontology)
- adenocarcinoma of endometrium
- Exact Synonym (Disease Ontology)
- adenocarcinoma of the Endometrium
- Exact Synonym (Disease Ontology)
- adenocarcinoma of uterus
- Exact Synonym (Disease Ontology)
- endometrial adenoacanthoma
- Exact Synonym (Disease Ontology)
- endometrial endometrioid adenocarcinoma
- Exact Synonym (Disease Ontology)
- endometrial endometrioid adenocarcinoma with squamous differentiation
- Exact Synonym (Disease Ontology)
- endometrioid adenoma or carcinoma
- Exact Synonym (Disease Ontology)
- endometrioid adenomas and carcinomas
- Exact Synonym (Disease Ontology)
- endometrioid carcinoma of Endometrium